Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy

Perspectives: * To set-up another clinical trial with this specific phenotype as the main stratification factor. Therefore a more aggressive or a more specific systemic treatment (with or without an immunomodulator) could be proposed to those selected patients in the field of personalized medicine. * To evaluate the use of the smear as a surrogate non-invasive technique to biopsy for immunomonitoring. * To use the CTC/PD-L1 assay as a liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint treatments. This specific subset of CTCs might represent metastatic cells with a high potential to escape T cell-mediated lysis and might therefore be the actual targets of immunotherapy.

Sex

Female

Minimum age

18 Years

Inclusion Criteria:

* Age ≥ 18 years.
* HPV-positive cervical cancer proven\* by biopsy.
* All FIGO stages cervical cancers which are the matter for radio-chemotherapy and exclusive brachytherapy indications.
* ECOG performance status ≤2.
* Ability to give informed consent.
* Patients must be affiliated to a Social Security System.
* Patient information and written informed consent form signed.

Exclusion Criteria:

* Adenocarcinoma of cervix.
* Known autoimmune disorder.
* History of HIV and/ or hepatitis infection.
* History of pelvic radiation or radio-chemotherapy.
* Recurrent or metastatic cervical cancer.
* Contra-indication for cisplatin.
* Patient pregnant and/or breastfeeding.
* History of other malignancy within the previous 5 years (except for appropriately treated melanoma skin carcinoma).
* Patients with psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

• BACKGROUNDFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9. PMID 25220842
• BACKGROUNDDe Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer. 2009 Oct;45(15):2632-9. doi: 10.1016/j.ejca.2009.07.019. Epub 2009 Aug 24. PMID 19709878
• BACKGROUNDzur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78. doi: 10.1016/0304-419x(96)00020-0. PMID 8876633
• BACKGROUNDMauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld JL, Deeg HJ. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39. doi: 10.1016/0360-3016(94)00430-S. PMID 7713791
• BACKGROUNDMell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1504-10. doi: 10.1016/j.ijrobp.2008.04.046. PMID 18640499
• BACKGROUNDKobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 2008 Sep;1(5):412-20. doi: 10.1038/mi.2008.33. Epub 2008 Jul 2. PMID 19079205
• BACKGROUNDJordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res. 2008 Apr 1;14(7):2028-35. doi: 10.1158/1078-0432.CCR-07-4554.